Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Acta Neuropathologica Communications|June 18, 2026
Higher disease reactivation risk in women after fingolimod withdrawalMarine Massy, Stefanie Marti, Adriane Kutllovci, et al.
Neurological Research and Practice|May 18, 2025
From routine to selective: how updated MRI guidelines reshape gadolinium use in GermanyMarc Pawlitzki, Alexander Stahmann, Niklas Frahm, et al.
Vaccines|December 23, 2023
Occurrence and Risk Factors of Relapse Activity after Vaccination against COVID-19 in People with Multiple Sclerosis: 1-Year Follow-Up Results from a Nationwide Longitudinal Observational StudyFiras Fneish, Niklas Frahm, Melanie Peters, et al.
Journal of Clinical Medicine|June 10, 2023
Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational StudyNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Multiple Sclerosis and Related Disorders|January 29, 2022
Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in GermanyJakob Holstiege, Manas K Akmatov, Kerstin Klimke, et al.
CNS Neuroscience & Therapeutics|July 10, 2026
Personality Traits and Their Association With Medication Non-Adherence in Patients With Multiple SclerosisPegah Mashhadiakbar, Michael Hecker, Niklas Frahm, et al.
Neurology and Therapy|January 12, 2022
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS RegistryNiklas Frahm, Firas Fneish, David Ellenberger, et al.
The Lancet Regional Health. Europe|September 12, 2022
SARS-CoV-2 vaccination in patients with multiple sclerosis in Germany and the United Kingdom: Gender-specific results from a longitudinal observational studyNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Therapeutic Advances in Neurological Disorders|April 1, 2024
Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS RegistryNiklas Frahm, David Ellenberger, Alexander Stahmann, et al.
Pageof 4